Clinically validated approaches to the treatment of autoimmune diseases. - Wikidata - wikimedia - TriplyDB

Clinically validated approaches to the treatment of autoimmune diseases.

Clinically validated approaches to the treatment of autoimmune diseases.

http://www.wikidata.org/entity/Q37668612

about

Polymer-conjugated inhibitors of tumor necrosis factor-α for local control of inflammation Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab The Clinical Usefulness of (18)F-FDG PET/CT in Patients with Systemic Autoimmune Disease.Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.The complex world of oligodendroglial differentiation inhibitors.Comparative In Vitro Immune Stimulation Analysis of Primary Human B Cells and B Cell Lines.Cytokine binding by polysaccharide-antibody conjugates."To be or not to be" for PET in rheumatology. A marriage of love or of convenience?OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics

P2860

Q26852346-F065931D-FF07-48C0-A8B1-F9E6FDAB8D89 Q27028100-38279E79-8AAC-4DBC-B390-393A88BB45B4 Q33573621-5C2150BD-2E0A-426C-B1EF-9E1F193F8898 Q33704370-63467C54-7214-4C6F-99DB-72B9BD03D1A7 Q37138277-35DBE5F6-5DDE-44B4-BA48-6880AAFFF481 Q37390483-EF0A0D79-5D75-42B6-A955-60BFB7866B80 Q37735799-BCA27290-0377-40FF-B643-0196C96AEA33 Q37790697-9C4AD645-E028-4F40-8C65-5D1B61A1CE73 Q37869047-47C0B907-29F3-40E1-AAA1-6E9E5EB1C8A8 Q38719791-384A3543-2283-4F43-B431-FF5EFA8CE6C0 Q39665229-F8F249FA-515E-46BC-B5E3-2E8280936B83 Q42367054-3B691B1F-84B9-45FD-BE1F-8BF94A8F8DCC Q57112652-EBF08B2D-C78B-422C-9ABD-356EDE289731

P2860

Clinically validated approaches to the treatment of autoimmune diseases.

http://www.wikidata.org/entity/Q37668612

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinically validated approaches to the treatment of autoimmune diseases.

@en

Clinically validated approaches to the treatment of autoimmune diseases.

@nl

type

label

Clinically validated approaches to the treatment of autoimmune diseases.

@en

Clinically validated approaches to the treatment of autoimmune diseases.

@nl

prefLabel

Clinically validated approaches to the treatment of autoimmune diseases.

@en

Clinically validated approaches to the treatment of autoimmune diseases.

@nl

P1433

Q37668612-6503E798-50D5-4AE9-ADC0-A0177F400FD4

P1476

Q37668612-A83F5036-2C36-4A6F-B16C-2D0255EBC503

P2093

Q37668612-4D06840F-AFCE-4811-93AD-4BD0597E448C

Q37668612-5531E1E2-59B6-4351-9C13-DBE7B5E08611

P2860

Q37668612-036E5282-0A9C-4CA6-B38D-59BAC163AB14

Q37668612-03905CAE-C412-4159-8908-D6E82CA2825C

Q37668612-06C03F9F-8D38-4F2F-B19B-B25916BF7A31

Q37668612-08D984A4-B61D-42BC-839E-F0AC0BBC9C49

Q37668612-0A19BDBA-6EEA-4133-BC74-0FBED306164D

Q37668612-0A372AE3-7A68-4A29-AC76-F6D351DB8485

Q37668612-0D9459B4-6AED-43A9-A473-11BE75DE4EF1

Q37668612-0DA68D19-3293-4A4A-BB9B-5AA8BCF4FD4B

Q37668612-0F9EC66E-CB98-49EC-97B6-20E63A6D6280

Q37668612-1293DE9B-46C6-43E8-8A02-9C418BC76331

P304

Q37668612-F557F6D0-A430-4F52-90DA-CE4195AA5297

P31

Q37668612-0C12E853-BB17-49A9-901F-4B32B281BE4A

P356

Q37668612-DAFCAABD-7572-4ABA-A08E-344F75228059

P407

Q37668612-C8674049-D963-4F66-8631-9E3BEA32B660

P433

Q37668612-1C18BE3D-7212-4A8B-982C-5EF1B5C69D09

P478

Q37668612-3F2B98C6-A689-4607-8235-384E243FE2A1

P577

Q37668612-EA607956-0184-427F-89BC-2BE29C8B9CB4

P698

Q37668612-D8F67994-A074-4DBA-A330-3080F68C8304

P356

13543780903418452

P1433

Expert Opinion on Investigational Drugs

P1476

Clinically validated approaches to the treatment of autoimmune diseases.

@en

P2093

Percy H Carter

http://www.w3.org/2001/XMLSchema#string

Qihong Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

Certolizumab pegol for the treatment of Crohn's disease

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

Infliximab maintenance therapy for fistulizing Crohn's disease

P304

195-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543780903418452

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20050823

http://www.w3.org/2001/XMLSchema#string